UBC Acquires REMS Company
Examoto is dedicated to the design, deployment, and operation of Risk Evaluation and Mitigation Strategy (REMS) services in the pharmaceutical market
UBC (Blue Bell, PA), a company providing integrated clinical, safety, and commercialization services for the biopharma industry, has announced that it has acquired Examoto, LLC, a Risk Evaluation and Mitigation Strategy (REMS) firm.
Examoto founder Jason Leedy commented, “Examoto’s technology and design innovations, in concert with UBC’s Project Management Office and related REMS services, creates a REMS powerhouse. We will collectively have the most comprehensive, proven capabilities for risk mitigation solutions for the pharma industry.”
Natalie O’Donnell, corporate vice president, UBC Safety and Risk Management, added, “Our acquisition of Examoto helps cement UBC’s status as a preeminent leader in this category, with a full-service REMS solution that leverages enhanced technologies and product innovations to help mitigate safety risk while optimizing the commercialization and delivery of products to market.”
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
